Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome
Version of Record online: 27 FEB 2006
Alimentary Pharmacology & Therapeutics
Volume 23, Issue 6, pages 787–795, March 2006
How to Cite
MANOLAKOPOULOS, S., BETHANIS, S., ELEFSINIOTIS, J., KARATAPANIS, S., TRIANTOS, C., SOURVINOS, G., TOULOUMI, G., ECONOMOU, M., VLACHOGIANNAKOS, J., SPANDIDOS, D., AVGERINOS, A. and TZOURMAKLIOTIS, D. (2006), Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Alimentary Pharmacology & Therapeutics, 23: 787–795. doi: 10.1111/j.1365-2036.2006.02806.x
- Issue online: 27 FEB 2006
- Version of Record online: 27 FEB 2006
- Publication data Submitted 30 October 2005 First decision 9 November 2005 Resubmitted 27 November 2005 Accepted 14 December 2005
Factors that predict response and breakthrough phenomenon to lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B have not been well defined.
To determine pre-treatment and on treatment variables that predict initial response and breakthrough in patients with HBeAg-negative chronic hepatitis B receiving long-term lamivudine.
Seventy-nine patients, with chronic HBeAg-negative hepatitis B, who received lamivudine for a median of 31 months were included in the study.
Initial virologic and biochemical response was observed in 73 (92%) and 70 (89%) patients, respectively, while 34 (47%) and 15 (21%) patients developed virological and biochemical breakthrough, respectively. High levels of necroinflammation in liver biopsy were associated with a higher probability of initial virological and biochemical response. Patients with pre-treatment serum hepatitis B virus DNA concentrations of more than 106 copies/mL were three times more likely to develop virologic breakthrough. Two patients died, one with baseline cirrhosis because of liver failure during biochemical breakthrough while the second death was liver and treatment unrelated.
In HBeAg-negative chronic hepatitis B, initial response to lamivudine therapy is associated with necroinflammation, while baseline serum hepatitis B virus DNA exceeding 106 copies/mL is a strong predictor for breakthrough because of drug-resistant mutations. Severe complications are uncommon and are associated with biochemical breakthrough and pre-existing cirrhosis.